FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313531957> ?p ?o ?g. }

• W4313531957 endingPage "101788" @default.
• W4313531957 startingPage "101788" @default.
• W4313531957 abstract "To describe a case of unilateral retinal arterial occlusive vasculitis after multiple intravitreal brolucizumab (IVBr) treatments for diabetic macular edema (DME).A 68-year-old Japanese woman who had a 3-year history of insulin-dependent diabetes mellitus presented with decreased vision in the right eye (oculus dexter, OD). After two consecutive IVBr (3 mg) treatments for DME, spaced 6 weeks apart, her best corrected visual acuity improved from 20/32 to 20/28 OD, as central macular thickness (CMT) decreased from 368 μm to 253 μm on optical coherence tomography (OCT). Immediately after the 3rd IVBr, the right intraocular pressure (IOP) increased. One week later, iritis (aqueous flares: 65.0 photon count [PC]/ms) was observed, followed by localized vasculitis 2 weeks later. One month after the 3rd IVBr, extensive vasculitis and vasculitis occluding retinal arterioles were identified. Based on the history of IVBr use and clinical findings, intraocular inflammation (IOI) and subsequent retinal arterial occlusive vasculitis due to IVBr was diagnosed. Topical steroid administration (i.e., eye drops and subtenon injection) resulted in improvement of IOI after 3 months. She subsequently underwent two intravitreal aflibercept injections for DME and panretinal photocoagulation (PRP) to prevent the development of proliferative changes due to diabetic retinopathy. One year after the diagnosis of retinal arterial occlusive vasculitis, the patient had slight loss of vision (20/50) compared to baseline, due to the progression of cataracts, and OCT angiography (OCTA) showed extensive non-perfusion area on the temporal side. However, other examination findings (IOP: 16 mmHg, aqueous flares: 30.5 PC/ms, CMT: 283 μm) were stable.Diagnosis and treatment at a relatively early stage after the onset of IOI prevented severe visual impairment in this case. Topical betamethasone eye drops reduced anterior chamber inflammation associated with IVBr; however, vascular sheathing worsened when topical drops alone was used. Occlusive retinal vasculitis, diagnosed with fluorescein angiography (FA) and OCTA, appeared to stabilize when subtenon triamcinolone injection was added to topical steroid administration. Because the central macula was not involved, severe vision loss was prevented. It is unknown if topical steroid administration would be adequate to prevent worsening of occlusive vasculitis in other cases. Although not used in this case, oral prednisone is one treatment option that may prevent severe vision loss. However, it requires monitoring of side effects, such as elevated blood glucose levels. PRP is also an option in cases where progression of proliferative changes is a concern, as was done in this case. With these considerations in mind, it is important to diagnose brolucizumab-associated IOI and subsequent retinal arterial occlusive vasculitis in DME patients early and initiate treatment to prevent severe visual impairment. Diagnosing new IOI and subsequent retinal arterial occlusive vasculitis is more difficult in DME than in neovascular age-related macular degeneration because of the inflammatory component often associated vascular occlusions. Therefore, early IOI diagnosis and follow-up using various instruments such as laser flare cell meter, wide-field color imaging, OCT/OCTA, and FA, in addition to usual comprehensive ophthalmologic examinations, is crucial." @default.
• W4313531957 created "2023-01-06" @default.
• W4313531957 creator A5022414598 @default.
• W4313531957 creator A5028539494 @default.
• W4313531957 creator A5051245230 @default.
• W4313531957 creator A5056051274 @default.
• W4313531957 creator A5083008418 @default.
• W4313531957 date "2023-03-01" @default.
• W4313531957 modified "2023-10-18" @default.
• W4313531957 title "Retinal arterial occlusive vasculitis after multiple intravitreal brolucizumab injections for diabetic macular edema" @default.
• W4313531957 cites W2050130686 @default.
• W4313531957 cites W2087224371 @default.
• W4313531957 cites W2115232314 @default.
• W4313531957 cites W2287587792 @default.
• W4313531957 cites W2808046946 @default.
• W4313531957 cites W3010184764 @default.
• W4313531957 cites W3014527467 @default.
• W4313531957 cites W3014659623 @default.
• W4313531957 cites W3035836792 @default.
• W4313531957 cites W3101914433 @default.
• W4313531957 cites W3126948741 @default.
• W4313531957 cites W3127081644 @default.
• W4313531957 cites W4200522992 @default.
• W4313531957 cites W4206960604 @default.
• W4313531957 cites W4212929213 @default.
• W4313531957 cites W4223573914 @default.
• W4313531957 doi "https://doi.org/10.1016/j.ajoc.2022.101788" @default.
• W4313531957 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36632338" @default.
• W4313531957 hasPublicationYear "2023" @default.
• W4313531957 type Work @default.
• W4313531957 citedByCount "4" @default.
• W4313531957 countsByYear W43135319572023 @default.
• W4313531957 crossrefType "journal-article" @default.
• W4313531957 hasAuthorship W4313531957A5022414598 @default.
• W4313531957 hasAuthorship W4313531957A5028539494 @default.
• W4313531957 hasAuthorship W4313531957A5051245230 @default.
• W4313531957 hasAuthorship W4313531957A5056051274 @default.
• W4313531957 hasAuthorship W4313531957A5083008418 @default.
• W4313531957 hasBestOaLocation W43135319571 @default.
• W4313531957 hasConcept C118487528 @default.
• W4313531957 hasConcept C126322002 @default.
• W4313531957 hasConcept C134018914 @default.
• W4313531957 hasConcept C2776015282 @default.
• W4313531957 hasConcept C2778257484 @default.
• W4313531957 hasConcept C2778328719 @default.
• W4313531957 hasConcept C2779134260 @default.
• W4313531957 hasConcept C2779829184 @default.
• W4313531957 hasConcept C2780248432 @default.
• W4313531957 hasConcept C2780347916 @default.
• W4313531957 hasConcept C2780827179 @default.
• W4313531957 hasConcept C555293320 @default.
• W4313531957 hasConcept C71924100 @default.
• W4313531957 hasConceptScore W4313531957C118487528 @default.
• W4313531957 hasConceptScore W4313531957C126322002 @default.
• W4313531957 hasConceptScore W4313531957C134018914 @default.
• W4313531957 hasConceptScore W4313531957C2776015282 @default.
• W4313531957 hasConceptScore W4313531957C2778257484 @default.
• W4313531957 hasConceptScore W4313531957C2778328719 @default.
• W4313531957 hasConceptScore W4313531957C2779134260 @default.
• W4313531957 hasConceptScore W4313531957C2779829184 @default.
• W4313531957 hasConceptScore W4313531957C2780248432 @default.
• W4313531957 hasConceptScore W4313531957C2780347916 @default.
• W4313531957 hasConceptScore W4313531957C2780827179 @default.
• W4313531957 hasConceptScore W4313531957C555293320 @default.
• W4313531957 hasConceptScore W4313531957C71924100 @default.
• W4313531957 hasLocation W43135319571 @default.
• W4313531957 hasLocation W43135319572 @default.
• W4313531957 hasLocation W43135319573 @default.
• W4313531957 hasOpenAccess W4313531957 @default.
• W4313531957 hasPrimaryLocation W43135319571 @default.
• W4313531957 hasRelatedWork W1978095703 @default.
• W4313531957 hasRelatedWork W2029549260 @default.
• W4313531957 hasRelatedWork W2058548650 @default.
• W4313531957 hasRelatedWork W2135859081 @default.
• W4313531957 hasRelatedWork W2412156743 @default.
• W4313531957 hasRelatedWork W2531551665 @default.
• W4313531957 hasRelatedWork W2594728658 @default.
• W4313531957 hasRelatedWork W2901245954 @default.
• W4313531957 hasRelatedWork W4205741474 @default.
• W4313531957 hasRelatedWork W4246627940 @default.
• W4313531957 hasVolume "29" @default.
• W4313531957 isParatext "false" @default.
• W4313531957 isRetracted "false" @default.
• W4313531957 workType "article" @default.